Description
Sunitinib
Each capsule contains Sunitinib malate 16.71 mg equivalent to Sunitinib … 12.5mg.
INDICATION
LuciSuni is a kinase inhibitor indicated for the treatment of: • Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • Advanced renal cell carcinoma (RCC). • Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. DOSAGE AND USE: GIST and RCC: • 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off. pNET: • 37.5 mg orally once daily, with or without food, continuously without a scheduled off- treatment period. Dose Modification: • Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual safety and tolerability.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD. No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciSuni during Pregnancy and Lactation.
Sunitinib
Each capsule contains Sunitinib malate 16.71 mg equivalent to Sunitinib … 25mg.
INDICATION
LuciSuni is a kinase inhibitor indicated for the treatment of: • Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • Advanced renal cell carcinoma (RCC). • Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.
DOSAGE AND USE
GIST and RCC: • 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off. pNET: • 37.5 mg orally once daily, with or without food, continuously without a scheduled off- treatment period. Dose Modification: • Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual safety and tolerability.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciSuni during Pregnancy and Lactation
Sunitinib
Each capsule contains Sunitinib malate 16.71 mg equivalent to Sunitinib … 50mg.
INDICATION
LuciSuni is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. Advanced renal cell carcinoma (RCC). Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.
DOSAGE AND USE
GIST and RCC: • 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off. pNET: • 37.5 mg orally once daily, with or without food, continuously without a scheduled off- treatment period. Dose Modification: • Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual safety and tolerability.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciSuni during Pregnancy and Lactation.
Reviews
There are no reviews yet.